期刊
JOURNAL OF CONTROLLED RELEASE
卷 200, 期 -, 页码 138-157出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2014.12.030
关键词
Cancer nanomedicine; Clinical trials; Nanoparticle; Liposome; Drug delivery; Targeting
资金
- Swiss Centre of Applied Human Toxicology (SCAHT)
Cancer is a leading cause of death worldwide. Currently available therapies are inadequate and spur demand for improved technologies. Rapid growth in nanotechnology towards the development of nanomedicine products holds great promise to improve therapeutic strategies against cancer. Nanomedicine products represent an opportunity to achieve sophisticated targeting strategies and multi-functionality. They can improve the pharma-cokinetic and pharmacodynamic profiles of conventional therapeutics and may thus optimize the efficacy of existing anti-cancer compounds. In this review, we discuss state-of-the-art nanoparticles and targeted systems that have been investigated in clinical studies. We emphasize the challenges faced in using nanomedicine products and translating them from a preclinical level to the clinical setting. Additionally, we cover aspects of nanocarrier engineering that may open up new opportunities for nanomedicine products in the clinic. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据